ENGLEWOOD, Colo. (AP) — What's stoking the Denver Broncos' surprising surge is the growing connection between rookie quarterback Bo Nix and veteran wide receiver Courtland Sutton. Whenever the Broncos (7-5) need a clutch catch, a key flag or a timely touchdown, Sutton is usually the one delivering it like he did Sunday when he caught eight passes on 10 targets for 97 yards and a pair of touchdowns that sparked the Broncos' come-from-behind 29-19 win at Las Vegas. “Courtland played tremendous,” coach Sean Payton said. Again. “He’s just reliable,” Nix said. “He's just always there when you need him.” Sutton's size (6-foot-4 and 216 pounds) and experience (he's in his seventh NFL season) make him an ideal target and safety valve for the rookie QB whose confidence is growing by the week. “He’s smart. He’s savvy. He makes plays when the ball’s in the air,” Nix said. “You can trust him. When it’s up in the air, it’s his or nobody’s. It’s not going to be a pick.” Nix's first touchdown toss to Sutton was an 18-yarder that allowed the QB to break Marlin Briscoe's 1968 Denver rookie record of 14 TD passes, and the two connected again with 5:30 left to make it a two-score game. The Broncos trailed 13-9 at halftime and Nix said they knew they had to get the ball into Sutton's hands more in the second half after he had caught the only pass thrown his way in the first half (for 17 yards). “Didn’t target him (much) in the first half,” Nix said. “We come out and say, ‘Look, Courtland, this is your half.’ We take over the game. He goes for two touchdowns. That just kind of speaks for what he means to our team.” Sutton has been on a tear after since he wasn't targeted a single time in Denver's 33-10 win at New Orleans on Oct. 17. (Payton mentioned as recently as last week what an anomaly that game was because there was a heavy diet of plays for Sutton that just didn't pan out for various reasons.) In his six games before that goose egg, Sutton had 21 catches on 49 targets for 277 yards and a touchdown. In the five games since, he's caught 36 of the 48 balls thrown his way for 467 yards and three TDs. Plus, he threw a touchdown pass to Nix on a “Philly Special” at Baltimore in Week 9. “I think we're just scratching the surface,” Sutton said. Thanks in part to the chemistry between Nix and Sutton, the Broncos are in position for the seventh and final playoff spot entering December. The passing game, thanks to the Nix-Sutton connection. The running game. Javonte Williams had just 2 yards on eight carries and Audric Estime ran three times for 15 yards against the Raiders' run-heavy fronts and a steady diet of blitzes. Jaleel McLaughlin saved the day with seven carries for 44 yards. OLB Nik Bonitto. His 10 sacks make him the first Denver defender with double-digit sacks since 2018, when Von Miller did it. Once again, the Broncos' special teams, with the exception of K Wil Lutz, who hasn't missed a field goal attempt or extra point since his protection unit cratered at Kansas City three weeks ago and allowed the Chiefs to block what would have been the game-winning kick as time expired. On Sunday, the Raiders had a successful fake punt and a 59-yard kickoff return. Payton isn't saying much about the injuries to DE Zach Allen (heel) and CB Riley Moss (knee) except that to him they're not serious setbacks for either player. 2 — The Broncos are two games above .500 for the first time since starting the 2021 season with three wins. The Broncos host Cleveland (3-8) on Monday night ahead of their bye week. AP NFL: https://apnews.com/hub/nfl
Vikings staying on track and in control behind Sam Darnold's composure and confidenceBREAKING: Impeachment Vote For South Korea's President Yoon Suk Yeol Fails
BREAKING: Tinubu opens up on fighting corruption in NigeriaNEW YORK (AP) — New York City Mayor Eric Adams met with President-elect Donald Trump's incoming “border czar” on Thursday, with the Democratic mayor expressing an enthusiasm to work with the incoming administration to pursue violent criminals in the city while Trump promises mass deportations. The mayor's meeting with Tom Homan, who will oversee the southern and northern borders and be responsible for deportation efforts in the Trump administration, came as Adams has welcomed parts of the president-elect's hardline immigration platform. Adams told reporters at a brief news conference that he and Homan agreed on pursuing people who commit violent crimes in the city but did not disclose additional details or future plans. “We’re not going to be a safe haven for those who commit repeated violent crimes against innocent migrants, immigrants and longstanding New Yorkers," he said. “That was my conversation today with the border czar, to figure out how to go after those individuals who are repeatedly committing crimes in our city.” The meeting marked Adams' latest and most definitive step toward collaborating with the Trump administration, a development that has startled critics in one of the country's most liberal cities. In the weeks since Trump’s election win, Adams has mused about potentially scaling back the city’s so-called sanctuary policies and coordinating with the incoming Trump administration on immigration. He has also said migrants accused of crimes shouldn’t have due process rights under the Constitution, though he eventually walked back those comments. The mayor further stunned Democrats when he sidestepped questions last week on whether he would consider changing parties to become a Republican, telling journalists that he was part of the “American party.” Adams later clarified that he would remain a Democrat. For Adams, a centrist Democrat known for quarreling with the city's progressive left, the recent comments on immigration follow frustration with the Biden Administration over its immigration policies and a surge of international migrants in the city. He has maintained that his positions have not changed and argues he is trying to protect New Yorkers, pointing to the law-and-order platform he has staked out throughout his political career and during his successful campaign for mayor. At his news conference Thursday, Adams reiterated his commitment to New York’s generous social safety net. “We’re going to tell those who are here, who are law-abiding, to continue to utilize the services that are open to the city, the services that they have a right to utilize, educating their children, health care, public protection,” he said. “But we will not be the safe haven for those who commit violent acts.” While the education of all children present in the U.S. is already guaranteed by a Supreme Court ruling, New York also offers social services like healthcare and emergency shelter to low-income residents, including those in the country illegally. City and state grants also provide significant access to lawyers, which is not guaranteed in the immigration court as they are in the criminal court. Still, Adams’ recent rhetoric has been seen by some critics as an attempt to cozy up to Trump, who could potentially offer a presidential pardon in his federal corruption case. Adams has been charged with accepting luxury travel perks and illegal campaign contributions from a Turkish official and other foreign nationals looking to buy his influence. He has pleaded not guilty. Homan, who was Trump’s former acting U.S. Immigration and Customs Enforcement director, also met this week with Republicans in Illinois, where he called on Gov. J.B. Pritzker and Chicago Mayor Brandon Johnson, both Democrats, to start negotiations over how Trump's mass deportation plans, according to local media. Separately, New York City officials this week announced continued efforts to shrink a huge emergency shelter system for migrants because of a steady decline in new arrivals. Among the planned shelter closures is a massive tent complex built on a federally owned former airport in Brooklyn, which advocates have warned could be a prime target for Trump's mass deportation plan. Elsewhere, Republican governors and lawmakers in some states are already rolling out proposals that could help him carry out his pledge to deport millions of people living in the U.S. illegally. Izaguirre reported from Albany, N.Y.
TV’s Dr. Oz invested in businesses regulated by agency Trump wants him to lead
TV’s Dr. Oz invested in businesses regulated by agency Trump wants him to leadJets' search for GM and coach will be assisted by former GMs Tannenbaum and SpielmanBEIRUT (AP) — Insurgents' stunning march across Syria gained speed on Saturday with news that they had reached the suburbs of the capital and with the government forced to deny rumors that President Bashar Assad had fled the country. The rebels' moves around Damascus, reported by an opposition war monitor and a rebel commander, came after the Syrian army withdrew from much of southern part of the country, leaving more areas, including two provincial capitals, under the control of opposition fighters. The advances in the past week were among the largest in recent years by opposition factions, led by a group that has its origins in al-Qaida and is considered a terrorist organization by the U.S. and the United Nations. As they have advanced, the insurgents, led by the Hayat Tahrir al-Sham group, or HTS, have met little resistance from the Syrian army. The U.N.’s special envoy for Syria, Geir Pedersen, on Saturday called for urgent talks in Geneva to ensure an “orderly political transition.” Speaking to reporters at the annual Doha Forum in Qatar, he said the situation in Syria was changing by the minute. In Damascus, people rushed to stock up on supplies. Thousands rushed the Syria border with Lebanon, trying to leave the country. Many shops in the capital were shuttered, a resident told The Associated Press, and those that remained open ran out of staples such as sugar. Some shops were selling items at three times the normal price. “The situation is very strange. We are not used to that,” the resident said, insisting on anonymity, fearing retributions. “People are worried whether there will be a battle (in Damascus) or not.” It was the first time that opposition forces reach the outskirts of Damascus since 2018, when Syrian troops recaptured the area following a yearslong siege. Amid the developments, Syria’s state media denied rumors flooding social media that Assad has left the country, saying he is performing his duties in Damascus. Assad's chief international backer, Russia, is busy with its war in Ukraine . Lebanon’s powerful Hezbollah, which at one point sent thousands of fighters to shore up Assad's forces, has been weakened by a yearlong conflict with Israel. Iran, meanwhile, has seen its proxies across the region degraded by regular Israeli airstrikes. Pedersen said a date for the talks in Geneva on the implementation of U.N. Resolution 2254 would be announced later. The resolution, adopted in 2015, called for a Syrian-led political process, starting with the establishment of a transitional governing body, followed by the drafting of a new constitution and ending with U.N.-supervised elections. Rami Abdurrahman, who heads the Britain-based Syrian Observatory for Human Rights, an opposition war monitor, said insurgents were in the Damascus suburbs of Maadamiyah, Jaramana and Daraya. Opposition fighters were also marching from eastern Syria toward the Damascus suburb of Harasta, he added. A commander with the insurgents, Hassan Abdul-Ghani, posted on the Telegram messaging app that opposition forces had begun the “final stage” of their offensive by encircling Damascus. Syria’s military, meanwhile, sent large numbers of reinforcements to defend the key central city of Homs, Syria’s third largest, as insurgents approached its outskirts. The shock offensive began Nov. 27, during which gunmen captured the northern city of Aleppo, Syria’s largest, and the central city of Hama , the country’s fourth largest city. HTS leader Abu Mohammed al-Golani told CNN in an interview Thursday from Syria that the aim is to overthrow Assad’s government. The Britain-based Observatory said Syrian troops have withdrawn from much of the two southern provinces and are sending reinforcements to Homs, where a battle is looming. If the insurgents capture Homs, they would cut the link between Damascus, Assad’s seat of power, and the coastal region where the president enjoys wide support. The Syrian army said in a statement Saturday that it has carried out redeployment and repositioning in Sweida and Daraa after its checkpoints came under attack by “terrorists.” The army said it is setting up a “strong and coherent defensive and security belt in the area,” apparently to defend Damascus from the south. The Syrian government has referred to opposition gunmen as terrorists since conflict broke out in March 2011. After the fall of the cities of Daraa and Sweida early Saturday, Syrian government forces remained in control of five provincial capitals — Damascus, Homs and Quneitra, as well as Latakia and Tartus on the Mediterranean coast. Tartus is home to the only Russian naval base outside the former Soviet Union while Latakia is home to a major Russian air base. In the gas-rich nation of Qatar, the foreign ministers of Iran, Russia and Turkey met to discuss the situation in Syria. Turkey is a main backer of the rebels. Qatar's top diplomat, Sheikh Mohammed bin Abdulrahman Al Thani, criticized Assad for failing to take advantage of the lull in fighting in recent years to address the country’s underlying problems. “Assad didn’t seize this opportunity to start engaging and restoring his relationship with his people,” he said. Sheikh Mohammed said he was surprised by how quickly the rebels have advanced and said there is a real threat to Syria’s “territorial integrity.” He said the war could “damage and destroy what is left if there is no sense of urgency” to start a political process. After the fall of the cities of Daraa and Sweida early Saturday, Syrian government forces remained in control of five provincial capitals — Damascus, Homs and Quneitra, as well as Latakia and Tartus on the Mediterranean coast. On Friday, U.S.-backed fighters of the Kurdish-led Syrian Democratic Forces captured wide parts of the eastern province of Deir el-Zour that borders Iraq as well as the provincial capital that carries the same name. The capture of areas in Deir el-Zour is a blow to Iran’s influence in the region as the area is the gateway to the corridor linking the Mediterranean to Iran, a supply line for Iran-backed fighters, including Lebanon’s Hezbollah. With the capture of a main border crossing with Iraq by the SDF and after opposition fighters took control of the Naseeb border crossing to Jordan in southern Syria, the Syrian government's only gateway to the outside world is the Masnaa border crossing with Lebanon. Karam reported from London. Associated Press writers Albert Aji in Damascus, Syria and Qassim Abdul-Zahra in Baghdad contributed to this report.Giants’ 10th straight loss showed once again that they need a young QB
Daix (France), New York City, (New York, United States), November 21, 2024 - Inventiva (Euronext Paris and Nasdaq: IVA) (the "Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH”), also known as non-alcoholic steatohepatitis ("NASH”), and other diseases with significant unmet medical needs, today reported its cash position as of September 30, 2024 and its revenues for the first nine months of 2024. Cash and cash equivalents As of September 30, 2024, the Company's cash and cash equivalents amounted to €13.9 million, compared to cash and cash equivalents at €26.9 million, short-term deposit 4 at €0.01 million, and long-term deposit 5 at €9.0 million as of December 31, 2023. Net cash used in operating activities amounted to (€64.2) million in the first nine months of 2024, compared to (€69.0) million for the same period in 2023 down by 7.0%. R&D expenses, mainly driven by the development of lanifibranor in MASH/NASH, for the first nine months of 2024 amounted to €71.7 million and were down 10.0% compared to the €79.6 million for the first nine months of 2023. The decrease in R&D expenses over the period is primarily due to the temporary voluntary pause in the recruitment of patients in the NATiV3 Phase 3 clinical trial of lanifibranor in MASH/NASH ("NATiV3") following the Suspected Unexpected Serious Adverse Reaction ("SUSAR”) previously reported in the first quarter of 2024 and, to a lesser extent, due to the completion of the LEGEND Phase 2a combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and type 2 diabetes ("T2D”). R&D expenses have started to increase as expected in the second half of 2024 following the restart of patient recruitment in NATiV3, as well as the planned clinical development activities and related costs associated with the NATiV3 for the second half of 2024. Net cash generated from investing activities for the first nine months of 2024 amounted to €8.7 million, compared to (€3.5) million used for the same period in 2023. The change is mostly due to the variation in term deposits between both periods. Net cash generated from financing activities for the first nine months of 2024 amounted to €42.3 million compared to €30.2 million in the same period in 2023. The change is due to (i) the second tranche of €25 million drawn in January 2024 under the unsecured loan agreement granted by the European Investment Bank ("EIB”) with the issue of 3,144,654 warrants to the EIB, and (ii) the issuance on July 18, 2024, of royalty certificates (the "2024 Royalty Certificates”) subscribed by Samsara BioCapital, and existing shareholders BVF Partners, NEA, Sofinnova, and Yiheng, for an amount of €20.1 million. The 2024 Royalty Certificates give the holders thereof the right to an annual payment of royalties equal to 3% of the potential future net sales of lanifibranor, if any, in the United States, the European Union and the United Kingdom over a 14-year term from the date of their issuance 6 . Over the first nine months of 2024, the Company did not record any exchange rate effect on cash and cash equivalents, compared to a negative exchange rate effect of (€0.7) million for the same period in 2023, due to the evolution of the EUR/USD exchange rate. Financial information after closing the accounts On October 14, 2024, the Company announced a multi-tranche equity financing (the "Equity Raise”) of up to €348 million from both new and existing investors 2 . The Company closed the first part of the first tranche of the Equity Raise on October 17, 2024, and issued 34,600,507 new ordinary shares (the "T1 New Shares”) at a price of €1.35 per T1 New Share, and 35,399,481 prefunded warrants to purchase ordinary shares in the Company at an exercise price of €0.01 and a subscription price of €1.34 per new ordinary share and received €94.1 million in gross proceeds (net proceeds approximately €86.6 million). The second part of the first tranche and the second and third tranches of the Equity Raise remain subject to satisfaction of specified conditions, and in particular shareholder approval. On October 14, 2024, the Company also announced that it had amended its license and collaboration agreement with Chia Tai Tianqing Pharmaceutical (Guangzhou) CO., LTD. ("CTTQ”). Pursuant to the amendment, if the Company receives commitments from investors to subscribe to an equity raise, in two or three tranches, prior to December 31, 2024, for an aggregate amount of at least €180 million, CTTQ shall pay to the Company (i) $10 million within 30 days of settlement-delivery of the new shares and prefunded warrants in the first tranche of the Equity Raise, (ii) $10 million upon the completion of the second tranche of the Equity Raise and (iii) $10 million upon the publication by the Company of positive topline data announcing that any key primary endpoint or key secondary endpoint of the NATiV3 trial, with any dosage regimen tested in the trial, have been met. Under the terms of the Amendment, the total amount of milestone payments remains unchanged, while the royalties that Inventiva is eligible to receive have been reduced to the low single digits. The signing of the Equity Raise satisfied the condition of receiving commitments for an aggregate amount of at least €180 million and the closing of the first part of the first tranche of the Equity Raise satisfied the condition (i) above. Subsequently, on November 18, 2024, the Company received the first milestone payment of $10 million from CTTQ pursuant to this amendment. Considering its current cost structure and forecasted expenditures and including (i) the receipt of €94.1 million in gross proceeds from the closing of the first part of the first tranche of the Equity Raise, and (ii) the first milestone of $10 million (gross proceeds) received under the amendment to the licensing agreement with CTTQ, the Company estimates that its cash, cash equivalents and deposits would enable it to finance its operations until the end of the second quarter of 2025 2 . The Company currently expects that the conditions for the closing of the second part of the first tranche of the Equity Raise will be satisfied in December 2024. Considering its current cost structure and forecasted expenditures, the Company estimates that the anticipated receipt of the proceeds (a gross amount of €21.4 million) from the second part of the first tranche of the Equity Raise announced on October 14, 2024 would be sufficient to extend the Company's ability to finance its operations until middle of the third quarter of 2025. Revenues The Company's revenues for the first nine months of 2024 amounted to €1.3 million, as compared to €1.9 million for the same period in 2023. *** Next key milestones expected Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with MASH/NASH and other diseases with significant unmet medical need. The Company benefits from a strong expertise and experience in the domain of compounds targeting nuclear receptors, transcription factors and epigenetic modulation. Inventiva is currently advancing one clinical candidate and has a pipeline of two preclinical programs. Inventiva's lead product candidate, lanifibranor, is currently in a pivotal Phase 3 clinical trial, NATiV3, for the treatment of adult patients with MASH/NASH, a common and progressive chronic liver disease. Inventiva's pipeline also includes odiparcil, a drug candidate for the treatment of adult MPS VI patients. As part of Inventiva's decision to focus clinical efforts on the development of lanifibranor, it suspended its clinical efforts relating to odiparcil and is reviewing available options with respect to its potential further development. Inventiva is also in the process of selecting a candidate for its Hippo signaling pathway program. The Company has a scientific team of approximately 90 people with deep expertise in the fields of biology, medicinal and computational chemistry, pharmacokinetics and pharmacology, and clinical development. It owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, as well as a wholly-owned research and development facility. Inventiva is a public company listed on compartment B of the regulated market of Euronext Paris (ticker: IVA, ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). www.inventivapharma.com Contacts Pascaline Clerc EVP, Strategy and Corporate Affairs [email protected] +1 202 499 8937 Tristan Roquet Montegon Aude Lepreux Julia Cailleteau Media relations [email protected] +33 1 53 96 83 83 Patricia L. Bank Investor relations [email protected] +1 415 513 1284 Important Notice This press release contains "forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release are forward-looking statements. These statements include, but are not limited to, unaudited financial information, forecasts and estimates with respect to Inventiva's cash resources, the anticipated proceeds from the Equity Raise, completion and timing of the Equity Raise, the satisfaction in part or full of the conditions precedent to closing of the various tranches of the Equity Raise and the timing thereof, and the exercise by the investors of the warrants and pre-funded warrants issued in connection with the Equity Raise, Inventiva's expectations regarding its collaboration agreement with CTTQ, including the achievement of specified milestones thereunder, forecasts and estimates with respect to Inventiva's pre-clinical programs and clinical trials, including design, protocol, duration, timing, recruitment costs, screening and enrollment for those trials, including the ongoing NATiV3 Phase 3 clinical trial with lanifibranor in MASH/NASH, the clinical development of and regulatory plans and pathway for lanifibranor, clinical trial data releases and publications, the information, insights and impacts that may be gathered from clinical trials, the potential therapeutic benefits of Inventiva's product candidates, including lanifibranor, potential regulatory submissions, approvals and commercialization, Inventiva's pipeline and preclinical and clinical development plans, the potential development of and regulatory pathway for odiparcil, future activities, expectations, plans, growth and prospects of Inventiva and its partners, and business and regulatory strategy, the potential commercialization of lanifibranor and achievement of any sales related thereto, potential payment of royalties and anticipated future performance. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, "believes”, "anticipates”, "expects”, "intends”, "plans”, "seeks”, "estimates”, "may”, "will”, "would”, "could”, "might”, "should”, "designed”, "hopefully”, "target”, "potential”, "opportunity”, "possible”, "aim”, and "continue” and similar expressions. Such statements are not historical facts but rather are statements of future expectations and other forward-looking statements that are based on management's beliefs. These statements reflect such views and assumptions prevailing as of the date of the statements and involve known and unknown risks and uncertainties that could cause future results, performance, or future events to differ materially from those expressed or implied in such statements. Actual events are difficult to predict and may depend upon factors that are beyond Inventiva's control. There can be no guarantees with respect to pipeline product candidates that the clinical trial results will be available on their anticipated timeline, that future clinical trials will be initiated as anticipated, that product candidates will receive the necessary regulatory approvals, or that any of the anticipated milestones by Inventiva or its partners will be reached on their expected timeline, or at all. Future results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates, due to a number of factors, including that interim data or data from any interim analysis of ongoing clinical trials may not be predictive of future trial results, the recommendation of the DMC may not be indicative of a potential marketing approval, Inventiva cannot provide assurance on the impacts of the Suspected Unexpected Serious Adverse Reaction (SUSAR) on enrollment or the ultimate impact on the results or timing of the NATiV3 trial or regulatory matters with respect thereto, that Inventiva is a clinical-stage company with no approved products and no historical product revenues, Inventiva has incurred significant losses since inception, Inventiva has a limited operating history and has never generated any revenue from product sales, Inventiva will require additional capital to finance its operations, in the absence of which, Inventiva may be required to significantly curtail, delay or discontinue one or more of its research or development programs or be unable to expand its operations or otherwise capitalize on its business opportunities and may be unable to continue as a going concern, Inventiva's ability to obtain financing and to enter into potential transactions and Inventiva's ability to satisfy in part or full the conditions precedent for additional tranches of the Equity Raise and the conditions with respect to CTTQ, and whether and to what extent the Warrants may be exercised and by which holders, Inventiva's future success is dependent on the successful clinical development, regulatory approval and subsequent commercialization of current and any future product candidates, preclinical studies or earlier clinical trials are not necessarily predictive of future results and the results of Inventiva's and its partners' clinical trials may not support Inventiva's and its partners' product candidate claims, Inventiva's expectations with respect to its clinical trials may prove to be wrong and regulatory authorities may require holds and/or amendments to Inventiva's clinical trials, Inventiva's expectations with respect to the clinical development plan for lanifibranor for the treatment of MASH/NASH may not be realized and may not support the approval of a New Drug Application, Inventiva and its partners may encounter substantial delays beyond expectations in their clinical trials or fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities, the ability of Inventiva and its partners to recruit and retain patients in clinical studies, enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside Inventiva's and its partners' control, Inventiva's product candidates may cause adverse drug reactions or have other properties that could delay or prevent their regulatory approval, or limit their commercial potential, Inventiva faces substantial competition and Inventiva's and its partners' business, and preclinical studies and clinical development programs and timelines, its financial condition and results of operations could be materially and adversely affected by geopolitical events, such as the conflict between Russia and Ukraine and related sanctions, impacts and potential impacts on the initiation, enrollment and completion of Inventiva's and its partners' clinical trials on anticipated timelines and the state of war between Israel and Hamas and the related risk of a larger conflict, health epidemics, and macroeconomic conditions, including global inflation, rising interest rates, uncertain financial markets and disruptions in banking systems. Given these risks and uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts, and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements. Please refer to the Universal Registration Document for the year ended December 31, 2023 filed with the Autorité des Marchés Financiers on April 3, 2024, as amended on October 14, 2024, the Annual Report on Form 20-F for the year ended December 31, 2023 filed with the Securities and Exchange Commission (the "SEC”) on April 3, 2024, and the Half-Year Report for the six months ended June 30, 2024 on Form 6-K filed with the SEC on October 15, 2024 for other risks and uncertainties affecting Inventiva, including those described under the caption "Risk Factors”, and in future filings with the SEC. Other risks and uncertainties of which Inventiva is not currently aware may also affect its forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. All information in this press release is as of the date of the release. Except as required by law, Inventiva has no intention and is under no obligation to update or review the forward-looking statements referred to above. Consequently, Inventiva accepts no liability for any consequences arising from the use of any of the above statements. 1 Non-audited financial information. 2 Press release of October 14, 2024 3 This estimate is based on the Company's current business plan and excludes any potential milestones payable to or by the Company and any additional expenditures related to the potential continued development of the odiparcil program or resulting from the potential in licensing or acquisition of additional product candidates or technologies, or any associated development the Company may pursue. The Company may have based this estimate on assumptions that are incorrect, and the Company may end up using its resources sooner than anticipated. 4 Short-term deposits were included in the category "other current assets” in the IFRS consolidated statement of financial position and were considered by the Company as liquid and easily available. 5 The long-term deposit had a two year-term, was accessible prior to the expiration of the term with a notice period of 31 days and was considered as liquid by the Company. 6 Press release of July 18, 2024 Attachment Inventiva - PR - Q3 2024 CA Cash - EN - 11 21 2024 - Final
Japan's famous sake joins UNESCO's cultural heritage list, a boost to brewers and enthusiasts
NUVVE HOLDING CORP. ANNOUNCES DATE OF SPECIAL MEETING OF STOCKHOLDERSHouse Republican takes aim at federal funding for California high-speed rail project
Ed Graney: Sorry, fans, tanking doesn’t enter into minds of playersAP Sports SummaryBrief at 7:07 a.m. EST
The report builds on Governor Kathy Hochul's efforts to advance New York's global reputation as the place where businesses come to grow, innovate, and create the future of emerging technologies. NEW YORK , Dec. 12, 2024 /PRNewswire/ -- (NYSE: IBM ) – The Emerging Technology Advisory Board (ETAB) today released its first report to elevate New York as an AI leader. The report provided recommendations to bolster the State's commitment to responsible development and implementation of AI. First introduced by Governor Kathy Hochul in June 2024 , the ETAB was established as an independent advisory board to chart the course for a thriving emerging technology ecosystem in New York State . The Advisory Board is co-chaired by IBM Chief Executive Officer Arvind Krishna and Girls Who Code Chief Executive Officer Dr. Tarika Barrett and is comprised of leaders from the private sector and nonprofit and foundation organizations. With input from over 40 external stakeholders and experts, the report details how New York is well-positioned to be at the forefront of AI advancement. This includes leveraging its robust economy, extensive tech talent pool, academic excellence, legacy for innovation, and groundbreaking investments in AI and AI-adjacent industries. In reviewing the state's current landscape, the Advisory Board also identified potential challenges, such as ensuring the workforce is equipped with the skills and resources necessary to succeed in the age of AI. The ETAB took a deeper look at how these challenges could impact New York organizations and communities – and, based on these insights, proposed three ambitions for the State of New York : Guided by these ambitions, the report sets forth nine recommendations – each backed by a thorough framework and next steps – designed to foster public-private partnerships and balance priorities of timely impact and sufficient scale necessary to help drive responsible AI adoption in New York . " New York State is furthering its legacy of innovation and invention for the rest of the world to follow, setting a standard of greatness – and we've only just begun," Governor Hochul said. "Since the beginning of my administration I have been laser-focused on bringing good paying jobs to this state, which is why we need ethical and responsible AI that improves the lives of all New Yorkers and delivers accessible, equitable and future proof jobs with it. I want to thank the members of the Emerging Technology Advisory Board, who took the time to form these recommendations. I look forward to reviewing the report and to working with experts and stakeholders from every sector as we forge an equitable and dynamic future for AI in New York ." "The Emerging Technology Advisory Board has delivered on its first goal to provide a blueprint that positions New York as a frontrunner in trustworthy AI," said Arvind Krishna . "This comprehensive set of recommendations will help drive an innovative AI ecosystem, ensure responsible AI deployment at scale, foster a resilient workforce, and empower all New Yorkers with equitable access to the benefits of AI." "The recommendations of the Emerging Technology Advisory Board reflect a collective effort to ensure that the advancement of artificial intelligence benefits industries and workers across New York ," said Tarika Barrett . "These comprehensive proposals aim not only to foster economic growth and innovation but also to uphold our commitment to a technological future that mirrors the diversity and values of our communities." As the Emerging Technology Advisory Board shares its recommendations with the State of New York , it underscores the joint effort, commitment and close collaboration it will take between the State's leadership, Advisory Board institutions, private sector, nonprofit organizations, philanthropic organizations, thought leaders and advocates to fortify New York as an innovation hub for future technologies. Read the full report here . About IBM IBM is a leading provider of global hybrid cloud and AI, and consulting expertise. We help clients in more than 175 countries capitalize on insights from their data, streamline business processes, reduce costs and gain the competitive edge in their industries. More than 4,000 government and corporate entities in critical infrastructure areas such as financial services, telecommunications and healthcare rely on IBM's hybrid cloud platform and Red Hat OpenShift to affect their digital transformations quickly, efficiently and securely. IBM's breakthrough innovations in AI, quantum computing, industry-specific cloud solutions and consulting deliver open and flexible options to our clients. All of this is backed by IBM's long-standing commitment to trust, transparency, responsibility, inclusivity and service. Visit www.ibm.com for more information. About Girls Who Code Girls Who Code is an international nonprofit organization working to close the gender gap in technology, and is leading the movement to inspire, educate, and equip students who identify as girls or nonbinary with the computing skills needed to pursue 21st century opportunities. Since launching in 2012, Girls Who Code has reached 670,000 students through our in-person and virtual programming, and 218,000 of our alumni are college or career-aged. Girls Who Code has sparked culture change through marketing campaigns and advocacy efforts, generating 14 Billion engagements globally. In 2019, the organization was named the #1 Most Innovative Non-Profit on Fast Company's Most Innovative Companies list, and in 2023 was named one of Fast Company's Brands That Matter. The organization was also named one of NonProfit Times' Best Nonprofits to Work For in 2022 and 2023. Media Contact Caitlin O'Neill , IBM Corporate Communications caitlin.oneill@ibm.com View original content to download multimedia: https://www.prnewswire.com/news-releases/new-york-emerging-technology-advisory-board-publishes-first-report-outlining-vision-to-elevate-leadership-in-ai-302330851.html SOURCE IBM
Published 18:13 IST, December 7th 2024 South Korea's President Yoon Suk Yeol survived the impeachment vote days after his short lived move of imposing martial rule in the country backfired. Seoul : The impeachment vote for South Korea's President Yoon Suk Yeol failed to succeed on Saturday. The chorus against Yoon had gained strength after his undemocratic and controversial move of declaring martial rule in the country. However, he failed to impose the martial rule after S Korean Parliament vote 190-0 against the ruling, earlier this week. Yoon survived an impeachment motion after his party members boycotted it. More to follow... Updated 18:29 IST, December 7th 2024